Spironolactone TO Prevent cardiovascular events in early stage Chronic Kidney Disease (CKD)

Spironolactone TO Prevent cardiovascular events in early stage Chronic Kidney Disease (CKD): A pilot trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN80658312

Enrollment

500

Registered

2013-04-04

Start date

2013-06-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Stage Chronic Kidney Disease Urological and Genital Diseases Chronic kidney disease, stage 1

Interventions

Spironolactone 25mg once daily (OD) or Placebo for 40 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female, age over 18 years 2. Diagnosis of CKD stage 3

Exclusion criteria

Exclusion criteria: 1. Diabetes Mellitus 2. Terminal disease or felt otherwise unsuitable by their general practitioner 3. Chronic heart failure i.e. a clinical diagnosis or known ejection fraction = 180/110 mmHg 10. Systolic blood pressure = 70mg/mmol 14. Serum potassium >= 5 mEq/L on screening blood test 15. Concomittant co-trimoxazole medication 16. Concomittant angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker medication 17. Pregnancy

Design outcomes

Primary

Measure	Time frame
Change in carotid-femoral pulse wave velocity measured at baseline and 40 weeks	—

Secondary

Measure	Time frame
1. Change in blood pressure measured at baseline and 40 weeks 2. Change in estimated Glomerular Filtration Rate (eGFR) measured at baseline and 40 weeks 3. Incidence of hyperkalaemia measured at baseline and 40 weeks 4. Incidence of hypotension (20mmHg systolic drop on standing) measured at baseline and 40 weeks	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 20, 2026